Tipelukast regulatory update

MediciNova said FDA granted Orphan Drug designation to tipelukast to treat idiopathic pulmonary fibrosis (IPF). MediciNova is finalizing a protocol for a Phase II trial of tipelukast for IPF. Tipeluka...